Symbols / BRNS Stock $0.64 +0.47% Barinthus Biotherapeutics plc

Healthcare • Biotechnology • United States • NGM
BRNS (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. William James Enright MBA
Exch · Country NGM · United States
Market Cap 26.22M
Enterprise Value -32.87M
Income -66.43M
Sales —
FCF (ttm) -28.04M
Book/sh 1.82
Cash/sh 1.73
Employees 14
Insider 10d —
IPO Apr 30, 2021
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -0.56
PEG —
P/S —
P/B 0.35
P/C —
EV/EBITDA 0.59
EV/Sales —
Quick Ratio 7.16
Current Ratio 7.76
Debt/Eq 15.19
LT Debt/Eq —
EPS (ttm) -1.64
EPS next Y -1.15
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-03-13
Earnings (prior) 2026-03-13
ROA -28.08%
ROE -65.02%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 40.85M
Shs Float 27.26M
Insider Own 13.12%
Instit Own 40.88%
Short Float 0.03%
Short Ratio 0.24
Short Interest 8.24K
52W High 2.92
vs 52W High -78.01%
52W Low 0.51
vs 52W Low 25.39%
Beta -0.60
Impl. Vol. —
Rel Volume 0.19
Avg Volume 39.97K
Volume 7.68K
Target (mean) $5.50
Tgt Median $5.50
Tgt Low $4.00
Tgt High $7.00
# Analysts 2
Recom None
Prev Close $0.64
Price $0.64
Change 0.47%
About

Barinthus Biotherapeutics plc, together with its subsidiaries, engages in the research, development, and commercialization of immunotherapies and vaccines in the United States and the United Kingdom. The company develops VTP-1000, an antigen-specific immune tolerance candidate, which is in Phase I clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease; and VTP-300, an immunotherapy, which is in Phase II clinical trial for the treatment of chronic hepatitis B virus infection. It has a license agreement with Oxford University Innovation for the development and commercialization of products with thermo-responsive adjuvant scaffolds; and U.S. National Institutes of Health for the evaluation of synthetic and polymer-based vaccine technology to prevent infectious disease and treat cancer in animal models. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is based in Germantown, Maryland.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$5.50
Mean price target
2. Current target
$0.64
Latest analyst target
3. DCF / Fair value
$-12.36
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.64
Low
$4.00
High
$7.00
Mean
$5.50

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-11-17 main HC Wainwright & Co. Buy → Buy $4
2025-03-21 reit HC Wainwright & Co. Buy → Buy $3
News
RSS: Latest BRNS news
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
-100.00%
14.97
+1766.46%
0.80
-98.21%
44.70
Operating Revenue
0.00
-100.00%
14.97
+1766.46%
0.80
-98.21%
44.70
Operating Expense
63.89
-4.28%
66.75
-17.85%
81.25
+71.05%
47.50
Research And Development
23.56
-38.40%
38.25
-7.63%
41.41
+0.74%
41.11
Selling General And Administration
40.83
+37.61%
29.67
-25.53%
39.84
+523.12%
6.39
General And Administrative Expense
40.83
+37.61%
29.67
-25.53%
39.84
+523.12%
6.39
Other Gand A
40.83
+37.61%
29.67
-25.53%
39.84
+523.12%
6.39
Other Operating Expenses
-0.51
+56.97%
-1.18
—
—
Total Expenses
63.89
-4.28%
66.75
-17.85%
81.25
+71.05%
47.50
Operating Income
-63.89
-23.39%
-51.78
+35.64%
-80.45
-2772.30%
-2.80
Total Operating Income As Reported
-70.56
-3.80%
-67.97
+19.00%
-83.91
-1976.57%
-4.04
EBITDA
-60.74
-9.69%
-55.37
+22.08%
-71.06
-1468.74%
5.19
Normalized EBITDA
-56.07
-29.90%
-43.16
+39.26%
-71.06
-1468.74%
5.19
Reconciled Depreciation
5.84
+0.78%
5.80
+6.83%
5.43
+25.58%
4.32
EBIT
-66.58
-8.84%
-61.17
+20.03%
-76.49
-8902.53%
0.87
Total Unusual Items
-4.67
+61.77%
-12.21
0.00
0.00
Total Unusual Items Excluding Goodwill
-4.67
+61.77%
-12.21
0.00
0.00
Special Income Charges
-4.67
+61.77%
-12.21
0.00
0.00
Other Special Charges
—
—
—
—
Impairment Of Capital Assets
4.67
-61.77%
12.21
0.00
—
Net Income
-66.43
-8.77%
-61.07
+16.73%
-73.35
-1473.03%
5.34
Pretax Income
-66.63
-8.83%
-61.23
+19.99%
-76.52
-9102.59%
0.85
Net Non Operating Interest Income Expense
1.91
-27.39%
2.62
-7.86%
2.85
-7.62%
3.08
Interest Expense Non Operating
0.05
-3.77%
0.05
+89.29%
0.03
+47.37%
0.02
Net Interest Income
1.91
-27.39%
2.62
-7.86%
2.85
-7.62%
3.08
Interest Expense
0.05
-3.77%
0.05
+89.29%
0.03
+47.37%
0.02
Interest Income Non Operating
1.96
-26.92%
2.68
-6.92%
2.88
-7.28%
3.10
Interest Income
1.96
-26.92%
2.68
-6.92%
2.88
-7.28%
3.10
Other Income Expense
-4.65
+61.48%
-12.07
-1215.90%
1.08
+90.83%
0.57
Other Non Operating Income Expenses
0.02
-88.15%
0.14
-87.52%
1.08
+90.83%
0.57
Gain On Sale Of Security
—
—
—
—
Tax Provision
-0.17
-297.73%
-0.04
+98.57%
-3.08
+31.22%
-4.47
Tax Rate For Calcs
0.00
+300.00%
0.00
-98.28%
0.00
-80.62%
0.00
Tax Effect Of Unusual Items
-0.01
-52.90%
-0.01
0.00
0.00
Net Income Including Noncontrolling Interests
-66.46
-8.62%
-61.18
+16.70%
-73.45
-1480.32%
5.32
Net Income From Continuing Operation Net Minority Interest
-66.43
-8.77%
-61.07
+16.73%
-73.35
-1473.03%
5.34
Net Income From Continuing And Discontinued Operation
-66.43
-8.77%
-61.07
+16.73%
-73.35
-1473.03%
5.34
Net Income Continuous Operations
-66.46
-8.62%
-61.18
+16.70%
-73.45
-1480.32%
5.32
Minority Interests
0.03
-72.48%
0.11
+9.00%
0.10
+376.19%
0.02
Normalized Income
-61.77
-26.40%
-48.87
+33.37%
-73.35
-1473.03%
5.34
Net Income Common Stockholders
-66.43
-8.77%
-61.07
+16.73%
-73.35
-1473.03%
5.34
Diluted EPS
-1.64
-5.81%
-1.55
+18.85%
-1.91
-1464.29%
0.14
Basic EPS
-1.64
-5.81%
-1.55
+18.85%
-1.91
-1464.29%
0.14
Basic Average Shares
40.53
+3.00%
39.35
+2.51%
38.39
+3.06%
37.25
Diluted Average Shares
40.53
+3.00%
39.35
+2.51%
38.39
+0.57%
38.17
Diluted NI Availto Com Stockholders
-66.43
-8.77%
-61.07
+16.73%
-73.35
-1473.03%
5.34
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
98.17
-38.77%
160.33
-25.26%
214.51
-20.61%
270.20
Current Assets
77.79
-38.14%
125.74
-19.86%
156.91
-26.35%
213.04
Cash Cash Equivalents And Short Term Investments
70.46
-36.33%
110.66
-22.12%
142.09
-26.90%
194.38
Cash And Cash Equivalents
70.46
-36.33%
110.66
-22.12%
142.09
-26.90%
194.38
Receivables
1.30
-81.72%
7.14
-46.49%
13.34
-26.07%
18.05
Accounts Receivable
—
—
0.00
-100.00%
5.85
Other Receivables
1.11
-84.48%
7.14
-30.76%
10.31
-15.48%
12.20
Taxes Receivable
0.20
0.00
-100.00%
3.03
0.00
Prepaid Assets
4.52
-22.89%
5.86
—
5.89
Restricted Cash
1.40
-19.68%
1.74
0.00
—
Other Current Assets
0.12
-66.57%
0.34
-76.66%
1.47
+141.24%
0.61
Total Non Current Assets
20.38
-41.08%
34.59
-39.96%
57.60
+0.76%
57.16
Net PPE
5.16
-56.10%
11.76
-39.40%
19.40
+23.50%
15.71
Gross PPE
12.75
-39.78%
21.18
-8.28%
23.09
+35.57%
17.03
Accumulated Depreciation
-7.59
+19.42%
-9.42
-155.42%
-3.69
-178.97%
-1.32
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
0.45
-66.09%
1.33
+20.31%
1.11
+6.44%
1.04
Other Properties
3.39
-67.90%
10.56
-20.64%
13.31
+10.31%
12.06
Leases
8.91
-4.01%
9.28
+7.02%
8.67
+120.91%
3.93
Goodwill And Other Intangible Assets
14.29
-34.90%
21.95
-41.19%
37.32
-7.81%
40.48
Goodwill
—
0.00
-100.00%
12.21
+0.00%
12.21
Other Intangible Assets
—
21.95
-12.59%
25.11
-11.18%
28.27
Other Non Current Assets
0.93
+5.56%
0.88
-0.11%
0.88
-9.63%
0.98
Total Liabilities Net Minority Interest
23.88
-20.92%
30.19
+9.75%
27.51
+1.88%
27.00
Current Liabilities
10.02
-36.02%
15.66
+24.28%
12.60
+2.91%
12.24
Payables And Accrued Expenses
6.60
-35.46%
10.22
+21.71%
8.40
-15.00%
9.88
Payables
0.35
-92.84%
4.89
+205.43%
1.60
-57.28%
3.75
Accounts Payable
0.35
-85.85%
2.47
+54.53%
1.60
-57.28%
3.75
Current Accrued Expenses
6.25
+17.13%
5.33
-21.54%
6.80
+10.82%
6.14
Pensionand Other Post Retirement Benefit Plans Current
0.00
-100.00%
1.77
-26.45%
2.41
+25.30%
1.93
Total Tax Payable
0.00
-100.00%
2.42
0.00
—
Current Debt And Capital Lease Obligation
2.02
+5.36%
1.92
+7.56%
1.78
+312.24%
0.43
Current Debt
—
—
—
—
Other Current Borrowings
—
—
—
—
Current Capital Lease Obligation
2.02
+5.36%
1.92
+7.56%
1.78
+312.24%
0.43
Current Deferred Liabilities
1.40
-19.68%
1.74
0.00
0.00
Current Deferred Revenue
1.40
-19.68%
1.74
0.00
0.00
Total Non Current Liabilities Net Minority Interest
13.86
-4.65%
14.54
-2.53%
14.91
+1.02%
14.76
Long Term Debt And Capital Lease Obligation
9.26
-8.22%
10.09
-9.87%
11.19
+34.18%
8.34
Long Term Capital Lease Obligation
9.26
-8.22%
10.09
-9.87%
11.19
+34.18%
8.34
Non Current Deferred Liabilities
0.25
-42.01%
0.44
-23.69%
0.57
-84.68%
3.75
Non Current Deferred Taxes Liabilities
0.25
-42.01%
0.44
-23.69%
0.57
-84.68%
3.75
Other Non Current Liabilities
4.35
+8.40%
4.01
+27.38%
3.15
+17.64%
2.68
Stockholders Equity
74.21
-42.93%
130.03
-30.39%
186.78
-23.10%
242.90
Common Stock Equity
74.21
-42.93%
130.03
-30.39%
186.78
-23.10%
242.90
Capital Stock
0.00
+0.00%
0.00
+0.00%
0.00
+0.00%
0.00
Common Stock
0.00
+0.00%
0.00
+0.00%
0.00
+0.00%
0.00
Share Issued
40.85
+1.53%
40.23
+4.12%
38.64
+2.55%
37.68
Ordinary Shares Number
40.85
+1.53%
40.23
+4.12%
38.64
+2.55%
37.68
Additional Paid In Capital
393.94
+0.12%
393.47
+1.78%
386.60
+1.87%
379.50
Retained Earnings
-304.09
-27.95%
-237.66
-34.59%
-176.59
-71.04%
-103.24
Gains Losses Not Affecting Retained Earnings
-15.73
+39.19%
-25.87
-10.95%
-23.32
+30.32%
-33.46
Minority Interest
0.08
-20.75%
0.11
-49.76%
0.21
-30.82%
0.30
Total Equity Gross Minority Interest
74.29
-42.91%
130.13
-30.41%
187.00
-23.11%
243.20
Total Capitalization
74.21
-42.93%
130.03
-30.39%
186.78
-23.10%
242.90
Working Capital
67.77
-38.44%
110.08
-23.71%
144.31
-28.13%
200.80
Invested Capital
74.21
-42.93%
130.03
-30.39%
186.78
-23.10%
242.90
Total Debt
11.28
-6.05%
12.01
-7.47%
12.98
+47.91%
8.77
Capital Lease Obligations
11.28
-6.05%
12.01
-7.47%
12.98
+47.91%
8.77
Net Tangible Assets
59.92
-44.56%
108.08
-27.69%
149.47
-26.16%
202.42
Tangible Book Value
59.92
-44.56%
108.08
-27.69%
149.47
-26.16%
202.42
Duefrom Related Parties Current
—
—
—
5.52
Foreign Currency Translation Adjustments
-15.73
+39.19%
-25.87
-10.95%
-23.32
+30.32%
-33.46
Other Equity Interest
0.09
+0.00%
0.09
+0.00%
0.09
-8.51%
0.09
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-47.98
-65.79%
-28.94
+43.17%
-50.92
-252.89%
-14.43
Cash Flow From Continuing Operating Activities
-47.98
-65.79%
-28.94
+43.17%
-50.92
-252.89%
-14.43
Net Income From Continuing Operations
-66.46
-8.62%
-61.18
+16.70%
-73.45
-1480.32%
5.32
Depreciation Amortization Depletion
5.84
+0.78%
5.80
+6.83%
5.43
+25.58%
4.32
Depreciation And Amortization
5.84
+0.78%
5.80
+6.83%
5.43
+25.58%
4.32
Other Non Cash Items
3.41
+44.63%
2.36
+67.04%
1.41
+21.43%
1.16
Stock Based Compensation
0.47
-90.06%
4.71
-6.84%
5.05
-48.82%
9.88
Asset Impairment Charge
5.79
-66.83%
17.47
0.00
—
Deferred Tax
-0.17
-297.73%
-0.04
+98.57%
-3.08
+29.10%
-4.34
Deferred Income Tax
-0.17
-297.73%
-0.04
+98.57%
-3.08
+29.10%
-4.34
Operating Gains Losses
3.50
+638.83%
-0.65
-108.62%
7.53
+129.82%
-25.25
Gain Loss On Investment Securities
—
—
—
—
Net Foreign Currency Exchange Gain Loss
3.74
+676.58%
-0.65
-108.62%
7.53
+130.24%
-24.91
Gain Loss On Sale Of PPE
-0.24
0.00
0.00
+100.00%
-0.35
Change In Working Capital
-0.36
-113.80%
2.60
-57.85%
6.17
+211.71%
-5.52
Change In Receivables
6.42
+373.65%
-2.35
-141.34%
5.67
+221.35%
-4.67
Changes In Account Receivables
—
0.00
-100.00%
5.80
+199.43%
-5.83
Change In Prepaid Assets
1.70
-53.23%
3.64
+65.59%
2.20
+201.38%
-2.17
Change In Payables And Accrued Expense
-6.00
-542.76%
1.35
+197.76%
-1.39
-173.24%
1.89
Change In Accrued Expense
-3.79
-931.80%
0.46
-77.12%
1.99
+165.38%
0.75
Change In Payable
-2.20
-345.21%
0.90
+126.58%
-3.38
-396.32%
1.14
Change In Account Payable
-2.20
-345.21%
0.90
+126.58%
-3.38
-396.32%
1.14
Change In Other Working Capital
-0.51
-129.11%
1.74
—
-0.18
Change In Other Current Assets
—
0.00
-100.00%
0.13
+133.07%
-0.39
Change In Other Current Liabilities
-1.98
-10.62%
-1.79
-302.02%
-0.45
0.00
Investing Cash Flow
0.42
+146.64%
-0.89
+83.52%
-5.41
+5.86%
-5.75
Cash Flow From Continuing Investing Activities
0.42
+146.64%
-0.89
+83.52%
-5.41
+5.86%
-5.75
Net PPE Purchase And Sale
0.42
+146.64%
-0.89
+83.52%
-5.41
+5.86%
-5.75
Purchase Of PPE
-0.04
+95.85%
-0.89
+83.52%
-5.41
+11.81%
-6.14
Sale Of PPE
0.45
0.00
0.00
-100.00%
0.39
Capital Expenditure
-0.04
+95.85%
-0.89
+83.52%
-5.41
+11.81%
-6.14
Net Business Purchase And Sale
—
—
—
0.00
Purchase Of Business
—
—
—
0.00
Financing Cash Flow
0.00
-99.91%
2.16
+15.54%
1.87
+476.00%
0.33
Cash Flow From Continuing Financing Activities
0.00
-99.91%
2.16
+15.54%
1.87
+476.00%
0.33
Net Issuance Payments Of Debt
—
—
0.00
+100.00%
-0.16
Issuance Of Debt
—
—
—
—
Repayment Of Debt
—
—
0.00
+100.00%
-0.16
Long Term Debt Issuance
—
—
—
—
Long Term Debt Payments
—
—
0.00
+100.00%
-0.16
Net Long Term Debt Issuance
—
—
0.00
+100.00%
-0.16
Short Term Debt Payments
—
—
—
-0.16
Net Short Term Debt Issuance
—
—
—
-0.16
Net Common Stock Issuance
0.00
-100.00%
2.16
+6.29%
2.04
+320.45%
0.48
Proceeds From Stock Option Exercised
0.00
0.00
0.00
0.00
Net Other Financing Charges
—
—
-0.16
—
Changes In Cash
-47.56
-71.89%
-27.67
+49.20%
-54.47
-174.30%
-19.86
Effect Of Exchange Rate Changes
7.01
+447.01%
-2.02
-193.09%
2.17
+1060.96%
0.19
Beginning Cash Position
112.40
-20.90%
142.09
-26.90%
194.38
-9.19%
214.05
End Cash Position
71.85
-36.07%
112.40
-20.90%
142.09
-26.90%
194.38
Free Cash Flow
-48.02
-60.95%
-29.83
+47.05%
-56.34
-173.90%
-20.57
Interest Paid Supplemental Data
—
—
0.00
0.00
Income Tax Paid Supplemental Data
—
—
0.00
0.00
Common Stock Issuance
0.00
-100.00%
2.16
+6.29%
2.04
+320.45%
0.48
Issuance Of Capital Stock
0.00
-100.00%
2.16
+6.29%
2.04
+320.45%
0.48
Net Preferred Stock Issuance
—
—
—
0.00
Preferred Stock Issuance
—
—
—
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category